Canada Markets close in 3 mins

Context Therapeutics Inc. (6K9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.9720+0.0140 (+0.72%)
As of 11:06AM CET. Market open.
Full screen
Previous Close1.9580
Open1.9560
Bid1.8580 x N/A
Ask1.9140 x N/A
Day's Range1.9560 - 1.9720
52 Week Range1.9560 - 8.9860
Volume540
Avg. Volume900
Market Cap22.353M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.4030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Context Therapeutics® Strengthens Research & Development Team

    Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&DPHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D. Context also announced the planned retirement of its current

  • GlobeNewswire

    Context Therapeutics® to Participate in Two January 2022 Investor Conferences

    PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022. Details of the events are as follows: Biotech Showcase™ 2022: The company’s presentation will be available for on-demand viewing dur

  • GlobeNewswire

    Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

    Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that data from the window-of-opportunity clinical trial of onapristone extended rel